Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity
An erratum to this article was published (J Diabetes Sci Technol, Mar 2026 ↗)
Authors' conclusion
The weight loss and glycemic lowering effects of GLP-1 RA therapy may be decreased in people with type 1 diabetes and obesity likely related to genetic causes. Further research is needed to understand GLP-1 RA mechanisms via energy regulating genes.
Study context
- Population
- Adults with T1D and obesity treated with GLP-1 RA therapy (including dual agonist tirzepatide)
- Participants
- 11 vs 15
- Exposure
- GLP-1 RA therapy in obesity likely vs unlikely related to genetic mutation(s)
- Genetic obesityn = 11
- Non-genetic obesityn = 15reference
- Outcome
- Change in body weight and HbA1c with GLP-1 RA therapy
- Follow-up
- Six months
Main finding
As reported in the abstract
Weight change
Genetic obesity
−5.75
± 9.46 · kg
Non-genetic obesity
−8.65
± 9.36 · kg
P = 0.44
Observational data: associations, not effects.
Further findings
Met goal weight loss ≥5% or HbA1c decrease ≥0.4% · fewer with genetic obesity
P = 0.04
| Outcome | Genetic obesity | Non-genetic obesity | P value |
|---|---|---|---|
| HbA1c change · six monthsNumerically lower reduction with genetic obesity | −0.28 ± 0.96 % | −0.43 ± 0.57 % | P = 0.64 |
Original publication
Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity. J Diabetes Sci Technol. Published 17 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →